# IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)

> **NCT06849986** · PHASE2 · RECRUITING · sponsor: **Fudan University** · enrollment: 45 (estimated)

## Conditions studied

- Soft Tissue Sarcomas
- Angiosarcoma
- Fibrosarcoma
- Leiomyosarcoma
- Pleomorphic Liposarcoma
- Malignant Peripheral Nerve Sheath Tumor (MPNST)
- Desmoplastic Small Round Cell Tumor

## Interventions

- **DRUG:** Tislelizumab+liposomal doxorubicin+ifosfamide

## Key facts

- **NCT ID:** NCT06849986
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-25
- **Primary completion:** 2027-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2026-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06849986

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06849986, "IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06849986. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*